EditorsAbout the SiteComes vs. MicrosoftUsing This Web SiteSite ArchivesCredibility IndexOOXMLOpenDocumentPatentsNovellNews DigestSite NewsRSS

02.11.18

Pharma Patents Have Become Harder to Enforce, So IAM Together With the Patent Microcosm Sets Up Lobbying Events

Posted in America, Deception, Europe, Patents at 9:31 am by Dr. Roy Schestowitz

IAM: When “alternative facts” are up for sale (if one can afford them)

Battistelli and IAM

Summary: The difficulty associated with enforcing certain types of patents (more so after Mayo and § 101) means that litigious attitudes and reliance on law firms are decreasing; IAM strikes back with another one of its many lobbying events (designed to shape public opinion and influence key decision-makers)

THE concept of patents is pretty much universal, but not all patents are created equal. There are different sorts of patents (“families”) pertaining to or belonging to different domains. Speaking of them all as though they’re the same is the recipe for meaningless debates. Not all patents, for example, are a matter of life or death. Ethical aspects apply in some cases; sometimes pure economics.

“Not all patents, for example, are a matter of life or death.”As we discovered quite recently, EPO oppositions can crash companies. In other words, wrong decisions (or intentions) to grant can be truly harmful and pretty awful to workers. Things get pretty freaky when patents are being claimed on life itself. Forward Pharma lost 30% of its value (or valuation) in just one day at the end of January. This was due to an EPO decision. Yes, some sectors are over-reliant on patents; there’s no question about it. Here’s an example from two days ago: (in the UK)

Shares in Scancell Holdings PLC rose sharply on Friday morning as the company said its Moditope immunotherapy platform is to be granted a European patent.

Scancell shares were up 11% on Friday at 13.54 pence per share.

How good is this European Patent (EP)? Well, there’s lack of certainty under Battistelli, so Scancell Holdings PLC might be the next Forward Pharma (a one-day collapse).

“What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.”Pacific Biosciences is meanwhile attempting to ‘compete’ by causing embargo of its rival, Oxford Nanopore. We wrote about it some days ago and received plenty of comments from people involved in this matter. It’s yet another one of those ITC examples where patent litigation is geared towards embargoes and bankruptcies, not innovation. Here is what the face-saving press release said (striving to justify waste of shareholders’ money, spent on litigation). This campaign of patent litigation by Pacific Biosciences backfired pretty badly. “Pacific Bio down 2% premarket on ITC patent ruling,” Wall Street media stated shortly thereafter. To quote: “The ITC interpreted the term “single-molecule sequencing” as limited to sequencing-by-synthesis approaches, determining that Oxford’s sequencing approach is not “single-molecule sequencing.””

What we have here is a cross-continental fight taken up to the ITC and failing, having heavily relied on a patent from the USPTO.

We have become increasingly supportive of the USPTO because it continues to deny patents on life and even software patents. PTAB helps and gravitates towards that. See the latest PTAB Life Sciences Report by John Cravero and Pharma Patents Blog writing about 35 U.S.C. § 101 rejections (not just based on Alice but also Mayo):

We’ve written previously about ex parte decisions of the Patent Trial and Appeal Board (PTAB) affirming patent eligibility rejections that seem to be inconsistent with the USPTO’s Subject Matter Eligibility Guidance. Apparently, applicants should be wary about appealing any rejection of a diagnostic method claim, because the PTAB may enter sua sponte patent eligibility rejections even if the examiner did not make a § 101 rejection.

Aside from § 101 there’s also 35 U.S.C. § 102. Hospira, based on this blog post, wins again. MedCo’s patent has been declared bogus as per § 102. To quote:

In the litigation, Hospira argued both (1) that the MedCo patents were invalid and (1) that Hospira’s proposed generic Angiomax drug would not infringe. The district court sided with MedCo on the first point (patents not invalid) but with Hospira on the second (patents not infringed). On appeal, the Federal Circuit has affirmed the non-infringement ruling but reversed on the on sale issue. The interesting portion is the on sale question.

Benjamin Anger and Jacob R. Rosenbaum wrote about it some days ago (very detailed).

“They get what they paid for. It’s pure lobbying/marketing.”As one can expect, the litigation ‘industry’ isn’t particularly happy about that. Many patents are being invalidated, which must be causing decrease in demand for patents and lawsuits (their main “offerings” or “services” or “products”).

There’s a “Pharma and Biotech IP Summit” being organised by IAM and as one can expect, the bill for this lobbying event is being footed by the main participants. “Finnegan is a Gold sponsor of IAM Magazine,” it says. There’s therefore a paid-for ‘talk’ (marketing). This not only helps Finnegan control the ‘debate’; it also keeps IAM on their ‘good side’ (maybe IAM will give Finnegan some more of these bogus ‘rewards’ or ‘endorsements’). “Jen Roscetti will present “The View from the United States” at @IAM_magazine’s #Pharma and #Biotech #IP Summit in London,” Finnegan wrote the other day. They get what they paid for. It’s pure lobbying/marketing.

“Either way, “Pharma and Biotech IP Summit” is an IAM sham. It’s sponsored by and dominated by the patent microcosm.”With all honesty, more people ought to speak out about IAM’s “business model”, which involves collecting cash, pushing agenda (in the form of ‘news’ or staged ‘debates’), offering bogus ‘endorsements’, and issuing 'studies' for people like Battistelli (bolstering his lies). There’s nothing benign about it. IAM is effectively a think tank and even some less senior insiders must have realise it. Several of them left, only to be replaced by relatively young and inexperienced writers. Tim Lince, it should be noted, is still listed as a writer at IAM, but he wrote nothing this year and only 1 (one!) blog post last year. Many writers left and perhaps associating with people Battistelli (as we last noted last night) won’t save them but only cause further harm.

Either way, “Pharma and Biotech IP Summit” is an IAM sham. It’s sponsored by and dominated by the patent microcosm. It’s like a propaganda platform facilitated by Joff Wild and his cohorts. He did the same for UPC (with cash from the EPO’s PR firm).

Share this post: These icons link to social bookmarking sites where readers can share and discover new web pages.
  • Digg
  • del.icio.us
  • Reddit
  • co.mments
  • DZone
  • email
  • Google Bookmarks
  • LinkedIn
  • NewsVine
  • Print
  • Technorati
  • TwitThis
  • Facebook

If you liked this post, consider subscribing to the RSS feed or join us now at the IRC channels.

Pages that cross-reference this one

What Else is New


  1. Saint-Germain's Poisonous Legacy of "Toxic Loans": The Emperor’s New Investment Guidelines

    Details about a secret vote to 'gamble' the EPO's budget on "a diversified portfolio managed by external experts"



  2. Saint-Germain's Poisonous Legacy of "Toxic Loans": Cautionary Tale for the EPO?

    Preface or background to a series of posts about Battistelli's French politics and why they can if not should alarm EPO workers



  3. Links 22/5/2018: Parrot 4.0, Spectre Number 4

    Links for the day



  4. Chamber of Commerce Lies About the United States Like It Lies About Other Countries for the Sole Purpose of Patent Maximalism

    When pressure groups that claim to be "US" actively bash and lie about the US one has to question their motivation; in the case of the Chamber of Commerce, it's just trying to perturb the law for the worse



  5. Links 21/5/2018: Linux 4.17 RC6, GIMP 2.10.2

    Links for the day



  6. The Attacks on the Patent Trial and Appeal Board (PTAB) Have Lost Momentum and the Patent Microcosm Begrudgingly Gives Up

    The Patent Trial and Appeal Board (PTAB), reaffirmed by the Court of Appeals for the Federal Circuit (CAFC) and now the Supreme Court as well, carries on preventing frivolous lawsuits; options for stopping PTAB have nearly been exhausted and it shows



  7. Software Patenting and Successful Litigation a Very Difficult Task Under 35 U.S.C. § 101

    Using loads of misleading terms or buzzwords such as "AI" the patent microcosm continues its software patents pursuits; but that's mostly failing, especially when courts come to assess pertinent claims made in the patents



  8. António Campinos Will Push Toward a France-Based Unified Patent Court (UPC)

    Frenchmen at EPO will try hard to bring momentum if not force to the Unified Patent Court; facts, however, aren't on their side (unlike Team UPC, which was always on Team Battistelli's side)



  9. In Apple v Samsung Patents That Should Never Have Been Granted May Result in a Billion Dollars in 'Damages'

    A roundup of news about Apple and its patent cases (especially Apple v Samsung), including Intel's role trying to intervene in Qualcomm v Apple



  10. Links 20/5/2018: KDevelop 5.2.2 and 5.2.3, FreeBSD 11.2 Beta 2

    Links for the day



  11. Aurélien Pétiaud's ILO Case (EPO Appeal) an Early Sign That ILO Protects Abusers and Power, Not Workers

    A famous EPO ‘disciplinary’ case is recalled; it’s another one of those EPO-leaning rulings from AT-ILO, which not only praises Battistelli amid very serious abuses but also lies on his behalf, leaving workers with no real access to justice but a mere illusion thereof



  12. LOT Network is a Wolf in Sheep's Clothing

    Another reminder that the "LOT" is a whole lot more than it claims to be and in effect a reinforcer of the status quo



  13. 'Nokification' in Hong Kong and China (PRC)

    Chinese firms that are struggling resort to patent litigation, in effect repeating the same misguided trajectories which became so notorious in Western nations because they act as a form of taxation, discouraging actual innovation



  14. CIPU is Amplifying Misleading Propaganda From the Chamber of Commerce

    Another lobbying event is set up to alarm lawmakers and officials, telling them that the US dropped from first to twelfth using some dodgy yardstick which favours patent extremists



  15. Patent Law Firms That Profit From Software Patent Applications and Lawsuits Still 'Pull a Berkheimer' to Attract Business in Vain

    The Alice-inspired (Supreme Court) 35 U.S.C. § 101 remains unchanged, but the patent microcosm endlessly mentions a months-old decision from a lower court (than the Supreme Court) to 'sell' the impression that everything is changing and software patents have just found their 'teeth' again



  16. A Year After TC Heartland the Patent Microcosm is Trying to 'Dilute' This Supreme Court's Decision or Work Around It

    IAM, Patent Docs, Managing IP and Patently-O want more litigation (especially somewhere like the Eastern District of Texas), so in an effort to twist TC Heartland they latch onto ZTE and BigCommerce cases



  17. Microsoft Attacks the Vulnerable Using Software Patents in Order to Maintain Fear and Give the Perception of Microsoft 'Safety'

    The latest patent lawsuits from Microsoft and its patent trolls (which it financially backs); these are aimed at feeble and vulnerable rivals of Microsoft



  18. Links 19/5/2018: Mesa 18.0.4 and Vim 8.1

    Links for the day



  19. Système Battistelli (ENArque) at the EPO is Inspired by Système Lamy in Saint-Germain-en Laye

    Has the political culture of Battistelli's hometown in France contaminated the governance of the EPO?



  20. In Australia the Productivity Commission Decides/Guides Patent Law

    IP Australia, the patent office of Australia, considers abolishing "innovation patents" but has not done so yet (pending consultation)



  21. Fishy Things Noticed Ahead of the Passage of a Lot of EPO Budget (Applicants' Money) to Battistelli's Other (and Simultaneous) Employer

    Observations and odd facts regarding the affairs of the council in St Germain; it certainly looks like Battistelli as deputy mayor and the mayor (Arnaud Péricard) are attempting to hide something



  22. Links 18/5/2018: AsteroidOS 1.0 Released, More Snyk/Black Duck FUD

    Links for the day



  23. Today's EPO Financially Rewards Abuses and Violations of the Law

    Battistelli shredded the European Patent Convention (EPC) to pieces and he is being rewarded for it, perpetuating a pattern of abuses (and much worse) being rewarded by the European Patent Organisation



  24. So-Called 'System Battistelli' is Destroying the EPO, Warn Insiders

    Low-quality patent grants by the EPO are a road to nowhere but a litigious climate in Europe and an unattractive EPO



  25. Rise in Patent Trolls' Activity in Germany Noted Amid Declining Patent Quality at the EPO

    The UPC would turn Europe into some sort of litigation ‘super-state’ — one in which national patent laws are overridden by some central, immune-from-the-law bureaucracy like the EPO; but thankfully the UPC continues its slow collapse



  26. EPO's Battistelli Taking Days Off Work for Political 'Duties' (Parties) in His French Theatre Where He'll Bring Buckets of EPO Budget (EPO Stakeholders' Money)

    More tales from Saint-Germain-en-Laye...



  27. Links 16/5/2018: Cockpit 168, GCompris 0.91, DHCP Bug

    Links for the day



  28. The EPO's 'Inventor Award' Scam: Part III

    An addendum to the "inventor of the year" affair, namely the case of Remmal



  29. Apple and Microsoft Are Still Suing Companies -- Using Patents of Course -- Which 'Dare' Compete (by Leveraging GNU/Linux)

    The vanity of proprietary software giants — as the latest news serves to reveal — targeting companies with patent lawsuits, both directly and indirectly



  30. The Anti-PTAB (Patent Quality), Anti-§ 101 Lobby is Losing Its Mind and It Has Become Amusing to Observe

    The rants about the Patent Trial and Appeal Board (PTAB), the courts and even the law itself have reached laughable levels; this reveals that the real agenda of patent maximalists is endless litigation and their methods boil down to those of an angry mob, not legal professionals


CoPilotCo

RSS 64x64RSS Feed: subscribe to the RSS feed for regular updates

Home iconSite Wiki: You can improve this site by helping the extension of the site's content

Home iconSite Home: Background about the site and some key features in the front page

Chat iconIRC Channel: Come and chat with us in real time

CoPilotCo

Recent Posts